TOPIC : Development of an outcomes-focused data platform to empower policy makers and clinicians to optimize care for patients with hematologic malignancies
Topic identifier: IMI2-2015-06-04
Planned opening date: 06-10-2015
Publication date: 06-10-2015
Types of action: RIA Research and Innovation action
Deadline model: two-stage
Deadline(s): 12-01-2016 17:00:00
2nd stage Deadline: 14-06-2016 17:00:00
Time Zone : (Brussels time)
Topic Description
Hematologic malignancies (HMs) account for about one-third of cancer cases in children and about one-third of cancer deaths.
TOPIC : Real World Outcomes Across the AD Spectrum (ROADS) to Better Care
Topic identifier: IMI2-2015-06-03
Planned opening date: 06-10-2015
Publication date: 06-10-2015
Types of action: RIA Research and Innovation action
Deadline model: two-stage
Deadline(s): 12-01-2016 17:00:00
2nd stage Deadline: 14-06-2016 17:00:00
Time Zone : (Brussels time)
Topic Description
A lack of consensus on appropriate patient-relevant outcome measures for AD and the difficulty in acquiring relevant high-quality evidence makes it challenging to make informed decisions regarding AD care.
Defining relevant outcomes and then integrating a comprehensive range of AD-relevant health and social care data should allow a broader assessment of risk-benefit of new treatments and technologies to improve those outcomes.
TOPIC : Establishing impact of RSV infection, resultant disease and public health approach to reducing the consequences
Topic identifier: IMI2-2015-06-02
Planned opening date: 06-10-2015
Publication date: 06-10-2015
Types of action: RIA Research and Innovation action
Deadline model: two-stage
Deadline(s): 12-01-2016 17:00:00
2nd stage Deadline: 14-06-2016 17:00:00
Time Zone : (Brussels time)
Topic Description
The Respiratory Syncytial Virus (RSV) causes severe respiratory illness in infants and children and has a significant burden in the elderly. It causes about 3.4 million hospitalisations globally each season.
There is a poor understanding of the burden of disease and costs associated. In addition, there is lack of clear predictability or classification of disease severity and long-term consequences.
TOPIC : Development of Quantitative System Toxicology (QST) approaches to improve the understanding of the safety of new medicines
Topic identifier: IMI2-2015-06-01
Planned opening date: 06-10-2015
Publication date: 06-10-2015
Types of action: RIA Research and Innovation action
Deadline model: two-stage
Deadline(s): 12-01-2016 17:00:00
2nd stage Deadline: 14-06-2016 17:00:00
Time Zone : (Brussels time)
Topic Description
Modeling is fundamental to drug development. But there is the need to develop innovative methodologies and practices to integrate the ‘omics analysis and network analysis with quantitative mechanism-based models to form a new approach to drug safety assessment. The emerging field of Quantitative Systems Pharmacology (QSP) seeks to address this methodological gap via the development of mathematical models that account for the mechanisms underlying the response of integrated biological systems at the level of target cells and organs.
As read on the European Commission website.
